苏州生物医药转化工程中心
王峰博士现任中国科学院生物物理所研究员，博士生导师，中科院生物物理所蛋白质与多肽药物创新平台执行主任，北京市生物大分子药物转化工程中心副主任，苏州生物医药转化工程中心主任，科技部重大专项首席科学家。 王峰博士曾在美国加州生物医药研究所(Calibr)、斯克利普斯研究所(The Scripps Research Institute)和诺华制药集团(Novartis)长期从事生物医药研究工作。在美国加州生物医药研究所担任首席研究员期间，负责生物大分子创新药物的前期研发，主持了30多个研发项目，部分临床候选药物已转让给大型国际药企进行产品开发，在药物筛选、设计和优化等方面积累了大量的经验，并拥有多个药物研发的新平台技术。
Feng Wang, PhD, Director, Suzhou Institute for Biomedical Research; Associate director and principal investigator at Key Laboratory of Protein and Peptide Therapeutics of Institute of Biophysics (IBP), Chinese Academy of Sciences (CAS). His research work focuses on developing new methods to identify and design novel antibody and antibody derivatives as therapeutics. Before joining IBP, Dr. Wang worked with Dr. Peter Schultz to establish California Institute for Biomedical Research (CaliBR) in 2012. He was principal investigator in charge of the group of protein therapeutics from 2012 to 2017. His work is currently supported by multiple state funding agencies and was funded by Bill & Melinda Gates Foundation, Juvenile Diabetes Research Foundation (JDRF), Pfizer and Merck & CO. Dr. Wang got his Ph.D in biochemistry at TAMU and performed his postdoc research work at The Scripps Research Institute, La Jolla, California.
张捷博士现任苏州生物医药转化工程中心常务副主任，拥有多年临床医学经验，于2000 年加入美国国际诺华制药集团，在诺华基因组研究所(GNF，美国加州圣地亚哥)工作的十三年里，参与了多项诺华全球新药研发项目。张捷博士是一位熟悉中国和欧美医药企业运营，具备企业战略规划制定和执行、医药创新和产业化等多方面能力的复合型人才。
Jay Zhang M.D./Ph.D, Deputy Director, Suzhou Institute for Biomedical Research, IBP, CAS; Dr. Zhang has over thirteen years’ experience in research and development at Novartis, with extensive experience in leading strategic planning & implementation process for biotech start-ups with strong global orientation.
管理团队
MANAGEMENT TEAM
苏州生物医药转化工程中心
苏州生物医药转化工程中心（以下简称“转化中心”）以生物医药创新药为主导，专注于从新药候选物的筛选优化到临床前研究等新药研发的重要阶段，力争成为具有国际 影响力的创新药物研发中心。
